Acorda Therapeutics Inc expected to post a loss of $1.56 a share - Earnings Preview

Acorda Therapeutics

03/11/2021 09:46

* Acorda Therapeutics Inc  ACOR.OQ   ACOR.O  is expected to show
a fall in quarterly revenue when it reports  results on November
9. 
* The Ardsley, New York-based company is expected to report  a
42.4% decrease in revenue to $30.572 million from $53.09 million
a year ago, according to the estimate from one analyst, based on
Refinitiv data. 
​* Refinitiv's mean analyst estimate for Acorda Therapeutics Inc
is for a loss of $1.56 per share. For the same quarter last
year, the company reported a loss of $1.38 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Acorda
Therapeutics Inc is $10​, about 59.3% above​ its last closing
price of $4.07. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -2.09       -2.09      -1.87     Beat    10.5
 Mar. 312021   -2.54       -2.54      -2.46     Beat    3.2
 Dec. 312020   -1.48       -1.48      -2.50     Missed  -68.9​
 Sep. 302020   -1.79       -1.78      -1.38     Beat    22.5
 ​​Jun.        -2.89       -2.88      -2.10     Beat    27
 302020                                                 
 Mar. 312020   -2.06       -2.49      -3.06     Missed  -23​
 Dec. 312019   -2.76       -2.43      -0.90     Beat    63
 Sep. 302019   -3.07       -3.07      -2.76     Beat    10.1
 This summary was machine generated November 3 at 09:46 GMT.  All
figures in US dollars unless otherwise stated